Victory Capital Management Inc. Has $6.15 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Victory Capital Management Inc. increased its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 56.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,266 shares of the company's stock after buying an additional 56,607 shares during the period. Victory Capital Management Inc. owned 0.27% of Apogee Therapeutics worth $6,149,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of APGE. EntryPoint Capital LLC increased its stake in Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after purchasing an additional 617 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in Apogee Therapeutics in the first quarter valued at approximately $212,000. Allspring Global Investments Holdings LLC bought a new stake in Apogee Therapeutics in the second quarter valued at approximately $143,000. Ameritas Investment Partners Inc. increased its stake in Apogee Therapeutics by 111.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock valued at $274,000 after purchasing an additional 2,172 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in Apogee Therapeutics in the first quarter valued at approximately $339,000. 79.04% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Carl Dambkowski sold 6,665 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $47.56, for a total value of $316,987.40. Following the completion of the transaction, the insider now owns 280,793 shares in the company, valued at $13,354,515.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $47.56, for a total transaction of $316,987.40. Following the completion of the transaction, the insider now owns 280,793 shares in the company, valued at $13,354,515.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jane Henderson sold 6,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the transaction, the chief financial officer now owns 200,871 shares of the company's stock, valued at approximately $9,694,034.46. The disclosure for this sale can be found here. Insiders sold 120,995 shares of company stock worth $5,218,774 over the last quarter. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Stock Performance

NASDAQ:APGE traded up $0.12 during trading hours on Monday, hitting $51.50. The stock had a trading volume of 345,375 shares, compared to its average volume of 514,275. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -9.79 and a beta of 2.74. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29. The business's 50 day moving average is $46.97 and its 200-day moving average is $49.70.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60). On average, sell-side analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.